Aurinia Pharmaceuticals Inc. — Director's Dealing 2021

Jan 4, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Aurinia Pharmaceuticals Inc. (AUPH)
CIK: 0001600620
Period of Report: 2021-01-01

Reporting Person: Donley Matthew Maxwell (Ex VP, Intern'l Operations)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$5.90	2029-08-19	Common Stock (250000)		Direct
Stock Option (right to buy)	$18.38	2030-01-28	Common Stock (126500)		Direct
Stock Option (right to buy)	$13.03	2030-12-21	Common Stock (236952)		Direct

Footnotes

F1: One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.

F2: Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.

F3: The shares subject to the option vest in thirty-six equal monthly installments from the grant date.